Nuvalent (NUVL) Retained Earnings (2020 - 2026)
Nuvalent's (NUVL) quarterly Retained Earnings came in at -$1.4 million in Q1 2026, up 99.79% YoY from -$678227.5 in Q1 2025, and up 99.86% on a QoQ basis from -$972.4 million in Q4 2025.
Nuvalent (NUVL) Retained Earnings (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Retained Earnings data on file, last reported at -$1.4 million in Q1 2026.
- Quarterly Retained Earnings rose 99.79% year-over-year to -$1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.4 million (up 99.79% YoY) and the FY2025 annual result came in at -$972.4 million, down 77.76% from the prior year.
- Retained Earnings climbed to -$1.4 million in Q1 2026, from -$972.4 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.4 million in Q2 2025 to a low of -$972.4 million in Q4 2025.
- A 5-year average of -$287.4 million and a median of -$214.4 million in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings plunged 57854.66% — and 2025, when it soared 100.35%.
- Tracing NUVL's Retained Earnings over 5 years: stood at -$494000.0 in 2022, then sank by 57854.66% to -$286.3 million in 2023, then sank by 91.08% to -$547.1 million in 2024, then slumped by 77.76% to -$972.4 million in 2025, then soared by 99.86% to -$1.4 million in 2026.
- The last three Retained Earnings figures came in at -$1.4 million (Q1 2026), -$972.4 million (Q4 2025), and -$853.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Nuvalent | 9.10 Bn | 9.10 Bn | - | -1.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.36 Mn |
| Dec 31, 2025 | -972.43 Mn |
| Sep 30, 2025 | -853.72 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | -631.60 Mn |
| Dec 31, 2024 | -547.05 Mn |
| Sep 30, 2024 | -472.29 Mn |
| Jun 30, 2024 | -387.94 Mn |
| Mar 31, 2024 | -330.78 Mn |
| Dec 31, 2023 | -286.30 Mn |
| Sep 30, 2023 | -1.31 Mn |
| Jun 30, 2023 | -214.36 Mn |
| Mar 31, 2023 | -185.27 Mn |
| Dec 31, 2022 | -494,000.00 |
| Sep 30, 2022 | -866,000.00 |
| Jun 30, 2022 | -1.13 Mn |
| Mar 31, 2022 | -1.02 Mn |
| Dec 31, 2021 | -228,000.00 |
| Sep 30, 2021 | -23,000.00 |
| Jun 30, 2021 | -48.51 Mn |